<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03557658</url>
  </required_header>
  <id_info>
    <org_study_id>THR-1442-C-455</org_study_id>
    <nct_id>NCT03557658</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment</brief_title>
  <official_title>A Phase 1, Open-label, Parallel-group Study to Evaluate the Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Bexagliflozin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theracos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theracos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the drug exposure and drug effects on subjects with&#xD;
      moderate hepatic impairment after a single oral dose of bexagliflozin tablets, 20mg. The&#xD;
      study will also evaluate how safe the study drug is and how well the study drug is tolerated&#xD;
      in subjects with moderate hepatic impairment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase 1, open-label, parallel-group study designed to assess the effect of&#xD;
      moderate hepatic impairment on the PK and PD of orally administered bexagliflozin tablets. A&#xD;
      total of 16 subjects comprising eight with moderate hepatic impairment (Child Pugh total&#xD;
      score 7 to 9) and eight healthy, matched controls, were enrolled and received a single oral&#xD;
      dose of bexagliflozin tablets, 20 mg, after an overnight fast. Food was withheld for at least&#xD;
      2 h after dosing. Water was allowed as desired except within 1 h of drug administration.&#xD;
&#xD;
      Blood samples were collected prior to dosing, and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16,&#xD;
      24, 36, and 48 h post-dose.&#xD;
&#xD;
      The unbound fraction of bexagliflozin at 24 h post dose and at the maximum plasma&#xD;
      concentration for each subject was determined by equilibrium dialysis.&#xD;
&#xD;
      Urine samples for PD analysis were collected for the 12 h interval preceding dosing and for&#xD;
      the 0 - 12 h, 12 - 24 h, 24 - 36 h, and 36 - 48 h intervals following dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 26, 2018</start_date>
  <completion_date type="Actual">December 26, 2018</completion_date>
  <primary_completion_date type="Actual">December 26, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Maximum Observed Plasma Concentration)</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Whole venous blood samples of 6mL were collected from a peripheral vein prior to dosing and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax (Time of Maximum Observed Plasma Concentration)</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Whole venous blood samples of 6mL were collected from a peripheral vein prior to dosing and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 (Apparent Terminal Elimination Half-life)</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Whole venous blood samples of 6mL were collected from a peripheral vein prior to dosing and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Whole venous blood samples of 6mL were collected from a peripheral vein prior to dosing and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Glucose Excretion 0-48 Hours</measure>
    <time_frame>0-48 hours</time_frame>
    <description>Pre-dose urine samples were collected from -12 to 0 h for baseline measurement of pharmacodynamic parameters. Post-dose urine samples were collected without preservative in four batches: 0 to 12 h, 12 to 24 h, 24 to 36h, and 36 to 48 h after dosing. Urine aliquots were prepared from well mixed collections for the assessment of pharmacodynamics.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Hepatic Impaired</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with hepatic impairment conforming to the Child-Pugh class B (total score 7-9)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with normal hepatic function</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexagliflozin</intervention_name>
    <description>Single oral dose of bexagliflozin tablet, 20 mg</description>
    <arm_group_label>Healthy Volunteer</arm_group_label>
    <arm_group_label>Hepatic Impaired</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Each subject had to meet the following criteria to be eligible for the study:&#xD;
&#xD;
          1. Be male or female adults between the age of 18 and 75 years&#xD;
&#xD;
          2. Have a body mass index (BMI) of 18.0 kg/m2 to 40.0 kg/m2&#xD;
&#xD;
          3. Have adequate venous access at multiple sites in both arms&#xD;
&#xD;
          4. Be willing to be confined to the clinical research facility as required by the&#xD;
             protocol&#xD;
&#xD;
          5. Be able to comprehend the explanation of the informed consent and be willing to&#xD;
             provide written informed consent in accordance with institutional and regulatory&#xD;
             guidelines&#xD;
&#xD;
          6. For subjects in the hepatic impairment group only: Be diagnosed with moderate hepatic&#xD;
             impairment with a Child-Pugh score 7 to 9 and be in stable general health apart from&#xD;
             hepatic impairment and its related conditions.&#xD;
&#xD;
          7. For subjects in the healthy control group only:&#xD;
&#xD;
               -  Be in general good health with matching demographics and baseline characteristics&#xD;
                  to individual subjects in the hepatic impairment group by age (± 10 years),&#xD;
                  weight (± 10%), sex, and smoking status&#xD;
&#xD;
               -  Exhibit neither evidence of an active infection nor undergoing any treatment with&#xD;
                  antibiotics at the time of Screening.&#xD;
&#xD;
        Prospective subjects who met any of the following criteria were ineligible to participate:&#xD;
&#xD;
          1. A clinically significant history of allergy to drugs or latex&#xD;
&#xD;
          2. A positive alcohol or drug result based on urine sample or breathalyzer testing at&#xD;
             Screening or at clinic admission&#xD;
&#xD;
          3. A donation of 400 mL of whole blood within two months, 200 mL of whole blood within&#xD;
             one month, or blood components or plasma within 14 days prior to Day 0&#xD;
&#xD;
          4. A history of exposure to an investigational drug within 30 days or 5 half-lives of the&#xD;
             investigational drug prior to Day 0, whichever was longer&#xD;
&#xD;
          5. A history of exposure to any SGLT2 inhibitor within 3 months prior to Day 0 or&#xD;
             participation in previous bexagliflozin clinical trials&#xD;
&#xD;
          6. A history of exposure to probenecid, rifampin, or any potential strong UGT1A9 inducers&#xD;
             or inhibitors within 2 months of Day 0&#xD;
&#xD;
          7. A clinically significant abnormal electrocardiogram (ECG) that includes but is not&#xD;
             limited to: heart rate &lt; 40 or &gt; 110 bpm, QRS&gt; 160 ms, QTc&gt; 480 ms (corrected by&#xD;
             Bazett's formula), or any clinically significant arrhythmia including Mobitz type II&#xD;
             2nd Degree Heart block and bifascicular block&#xD;
&#xD;
          8. A history of human immunodeficiency virus (HIV) infection or a positive titer for HIV&#xD;
             antibody&#xD;
&#xD;
          9. A history of vaccination (with the exception of the flu vaccine) within 30 days prior&#xD;
             to Day 0&#xD;
&#xD;
         10. An estimated glomerular filtration rate (eGFR) &lt; 60 mL·min-1 per 1.73 m2 as calculated&#xD;
             by the modification of diet in renal disease study equation&#xD;
&#xD;
         11. Severe or moderate renal dysfunction or a history of kidney, other organ, bone marrow,&#xD;
             or stem cell transplant&#xD;
&#xD;
         12. If male, unwilling to refrain from donating sperm or to use appropriate birth control&#xD;
             when engaging in sexual intercourse for the duration of the study and a period of 14&#xD;
             days after discharge from the clinic. Surgically sterile male subjects were eligible&#xD;
&#xD;
         13. If female and of childbearing potential, unwilling to use an adequate method of&#xD;
             contraception to avoid or prevent pregnancy for the duration of the study and 14 days&#xD;
             after discharge from the clinic. Surgically sterile (as a result of hysterectomy or&#xD;
             bilateral oophorectomy), or postmenopausal (absence of menses greater than 12 months&#xD;
             and age &gt; 45 years) female subjects were eligible. All females were to have had a&#xD;
             negative pregnancy test at Screening and at clinic admission&#xD;
&#xD;
         14. Unwillingness to forgo consumption of grapefruit and grapefruit products from 7 days&#xD;
             prior to Day 0 through discharge from the clinic&#xD;
&#xD;
         15. Pre existing thrombocytopenia (platelet blood count &lt; 30,000 platelets) at Screening&#xD;
             or other clinically significant findings in complete blood count (CBC) test.&#xD;
&#xD;
         16. A history of current febrile illness, hepatocellular carcinoma, acute liver disease,&#xD;
             severe hepatic encephalopathy, or biliary liver cirrhosis.&#xD;
&#xD;
         17. A history of significant acute medical illness (new conditions and/or exacerbation of&#xD;
             pre existing conditions or major surgery within 4 weeks of study drug administration),&#xD;
             active alcoholic hepatitis, current or recent (within 2 months before Day 0) history&#xD;
             of significant gastrointestinal disease&#xD;
&#xD;
         18. Clinical evidence of severe ascites, as judged by the Investigator&#xD;
&#xD;
         19. A history of surgical portosystemic shunt&#xD;
&#xD;
         20. For subjects in the healthy control group only:&#xD;
&#xD;
               -  A seated systolic blood pressure (SBP) of &lt; 90 or &gt; 140 mmHg, confirmed by repeat&#xD;
                  measurement&#xD;
&#xD;
               -  A seated diastolic blood pressure (DBP) of &lt; 40 or &gt; 90 mmHg&#xD;
&#xD;
               -  A history of vitamin preparation or supplement use (including St. John's Wort and&#xD;
                  ginseng) within 7 days prior to Day 0, or caffeine and methylxanthine (e.g., tea,&#xD;
                  chocolate) containing foods/beverages within 48 h prior to Day 0&#xD;
&#xD;
               -  A history of prescription or over-the-counter (OTC) drug use within 7 days or 5&#xD;
                  half lives of the drug, whichever was longer, prior to Day 0&#xD;
&#xD;
               -  A history of liver disease or liver injury as indicated by an alanine&#xD;
                  aminotransferase (ALT), aspartate aminotransferase (AST), &gt; 2.5 × the upper limit&#xD;
                  of normal (ULN) at Screening, or serum bilirubin &gt; 1.5 × ULN&#xD;
&#xD;
               -  Evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection&#xD;
&#xD;
         21. For subjects in the hepatic impairment group only:&#xD;
&#xD;
               -  A seated SBP of &lt; 80 or &gt; 160 mmHg, confirmed by repeat measurement&#xD;
&#xD;
               -  A seated DBP of &lt; 40 or &gt; 100 mmHg&#xD;
&#xD;
               -  A history of any new prescription medication within 30 days prior to Day 0&#xD;
&#xD;
               -  A history of fluctuating or rapidly deteriorating hepatic function or the&#xD;
                  production of widely varying or worsening clinical and/or laboratory signs of&#xD;
                  hepatic impairment within the screening period&#xD;
&#xD;
         22. Any other serious medical condition that, in the opinion of the Investigator, would&#xD;
             pose a significant risk to the subject or interfere with the interpretation of safety,&#xD;
             PK, or PD data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. P. Lock, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Theracos Sub, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Site 1</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 2</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 4, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <results_first_submitted>April 5, 2021</results_first_submitted>
  <results_first_submitted_qc>May 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2021</results_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bexagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT03557658/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 31, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT03557658/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Normal Hepatic Function</title>
          <description>Healthy subjects with normal hepatic function. Each subject will receive a single oral dose of bexagliflozin, 20 mg.</description>
        </group>
        <group group_id="P2">
          <title>Moderate Hepatic Impairment</title>
          <description>Subjects with hepatic impairment conforming to the Child-Pugh class B (total score 7-9). Each subject will receive a single oral dose of bexagliflozin tablet, 20 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Normal Hepatic Function</title>
          <description>Healthy subjects with normal hepatic function. Each subject will receive a single oral dose of bexagliflozin, 20 mg.</description>
        </group>
        <group group_id="B2">
          <title>Moderate Hepatic Impairment</title>
          <description>Subjects with hepatic impairment conforming to the Child-Pugh class B (total score 7-9). Each subject will receive a single oral dose of bexagliflozin tablet, 20 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.1" spread="4.16"/>
                    <measurement group_id="B2" value="59.9" spread="4.58"/>
                    <measurement group_id="B3" value="58.5" spread="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Child-Pugh Total Score</title>
          <description>The Child-Pugh classification score was used to determine the severity of hepatic impairment. A patient was rated a score of 1 to 3 for each of the 5 categories: encephalopathy, ascites, bilirubin, albumin and INR. The total score was the sum of the scores for each category with a minimum of 5 and a maximum of 15. A subject would have a mild hepatic impairment with a Child-Pugh score of 5 to 6, a moderate impairment with a score of 7 to 9 and a severe impairment with a score of 10 to 15. A subject with normal hepatic function would have a score of 0 assigned.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0"/>
                    <measurement group_id="B2" value="8.3" spread="0.89"/>
                    <measurement group_id="B3" value="4.13" spread="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Current Smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Former Smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pack Years of Cigarette Smoking</title>
          <population>Number analyzed only include current and former smokers</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" spread="5.27"/>
                    <measurement group_id="B2" value="13.2" spread="20.09"/>
                    <measurement group_id="B3" value="9.23" spread="14.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Observed Plasma Concentration)</title>
        <description>Whole venous blood samples of 6mL were collected from a peripheral vein prior to dosing and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
        <time_frame>Up to 48 hours</time_frame>
        <population>The Pharmacokinetic (PK) population included all subjects without major protocol violations who were dispensed the study drug and provided an observation for at least one primary PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Hepatic Function</title>
            <description>Healthy subjects with normal hepatic function. Each subject will receive a single oral dose of bexagliflozin, 20 mg.</description>
          </group>
          <group group_id="O2">
            <title>Moderate Hepatic Impairment</title>
            <description>Subjects with hepatic impairment conforming to the Child-Pugh class B (total score 7-9). Each subject will receive a single oral dose of bexagliflozin tablet, 20 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Observed Plasma Concentration)</title>
          <description>Whole venous blood samples of 6mL were collected from a peripheral vein prior to dosing and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
          <population>The Pharmacokinetic (PK) population included all subjects without major protocol violations who were dispensed the study drug and provided an observation for at least one primary PK endpoint.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Bexagliflozin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.8" spread="34.0"/>
                    <measurement group_id="O2" value="96.5" spread="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unbound Bexagliflozin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="45.5"/>
                    <measurement group_id="O2" value="6.6" spread="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters for total bexagliflozin by hepatic function group.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.0 - 125.00%.</non_inferiority_desc>
            <param_type>Point Estimate</param_type>
            <param_value>106.22</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>78.34</ci_lower_limit>
            <ci_upper_limit>144.02</ci_upper_limit>
            <estimate_desc>Point Estimate is the estimated ratio of exponentiated mean difference of log-transformed PK parameter from ANOVA. Confidence interval is obtained from ANOVA with hepatic function group as a fixed effect, and the subject as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters for unbound bexagliflozin by hepatic function group</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.00 - 125.00%.</non_inferiority_desc>
            <param_type>Point Estimate</param_type>
            <param_value>110.84</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>75.34</ci_lower_limit>
            <ci_upper_limit>163.06</ci_upper_limit>
            <estimate_desc>Point Estimate is the estimated ratio of exponentiated mean difference of log-transformed PK parameter from ANOVA. Confidence interval is obtained from ANOVA with hepatic function group as a fixed effect, and the subject as a random effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax (Time of Maximum Observed Plasma Concentration)</title>
        <description>Whole venous blood samples of 6mL were collected from a peripheral vein prior to dosing and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
        <time_frame>Up to 48 hours</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Hepatic Function</title>
            <description>Healthy subjects with normal hepatic function. Each subject will receive a single oral dose of bexagliflozin, 20 mg.</description>
          </group>
          <group group_id="O2">
            <title>Moderate Hepatic Impairment</title>
            <description>Subjects with hepatic impairment conforming to the Child-Pugh class B (total score 7-9). Each subject will receive a single oral dose of bexagliflozin tablet, 20 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (Time of Maximum Observed Plasma Concentration)</title>
          <description>Whole venous blood samples of 6mL were collected from a peripheral vein prior to dosing and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
          <population>PK population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Bexagliflozin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.00" upper_limit="3.05"/>
                    <measurement group_id="O2" value="3.00" lower_limit="2.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unbound Bexagliflozin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.00" upper_limit="3.05"/>
                    <measurement group_id="O2" value="3.00" lower_limit="2.00" upper_limit="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T1/2 (Apparent Terminal Elimination Half-life)</title>
        <description>Whole venous blood samples of 6mL were collected from a peripheral vein prior to dosing and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
        <time_frame>Up to 48 hours</time_frame>
        <population>The adjusted r2 value for the regression for Subject 4551383007 (normal hepatic function group) was less than 0.7. The T1/2 was not estimated.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Hepatic Function</title>
            <description>Healthy subjects with normal hepatic function. Each subject will receive a single oral dose of bexagliflozin, 20 mg.</description>
          </group>
          <group group_id="O2">
            <title>Moderate Hepatic Impairment</title>
            <description>Subjects with hepatic impairment conforming to the Child-Pugh class B (total score 7-9). Each subject will receive a single oral dose of bexagliflozin tablet, 20 mg</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 (Apparent Terminal Elimination Half-life)</title>
          <description>Whole venous blood samples of 6mL were collected from a peripheral vein prior to dosing and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
          <population>The adjusted r2 value for the regression for Subject 4551383007 (normal hepatic function group) was less than 0.7. The T1/2 was not estimated.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Bexagliflozin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="40.2"/>
                    <measurement group_id="O2" value="9.5" spread="51.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unbound Bexagliflozin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="44.1"/>
                    <measurement group_id="O2" value="10.6" spread="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)</title>
        <description>Whole venous blood samples of 6mL were collected from a peripheral vein prior to dosing and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
        <time_frame>Up to 48 hours</time_frame>
        <population>The adjusted r2 value for the regression for Subject 4551383007 (normal hepatic function group) was less than 0.7. The AUC0-inf was not estimated.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Hepatic Function</title>
            <description>Healthy subjects with normal hepatic function. Each subject will receive a single oral dose of bexagliflozin, 20 mg.</description>
          </group>
          <group group_id="O2">
            <title>Moderate Hepatic Impairment</title>
            <description>Subjects with hepatic impairment conforming to the Child-Pugh class B (total score 7-9). Each subject will receive a single oral dose of bexagliflozin tablet, 20 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)</title>
          <description>Whole venous blood samples of 6mL were collected from a peripheral vein prior to dosing and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).</description>
          <population>The adjusted r2 value for the regression for Subject 4551383007 (normal hepatic function group) was less than 0.7. The AUC0-inf was not estimated.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Bexagliflozin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="695.8" spread="25.3"/>
                    <measurement group_id="O2" value="893.0" spread="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unbound Bexagliflozin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" spread="31.0"/>
                    <measurement group_id="O2" value="63.3" spread="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters for total bexagliflozin by hepatic function group</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.00 - 125.00%.</non_inferiority_desc>
            <param_type>Point Estimate</param_type>
            <param_value>128.34</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.98</ci_lower_limit>
            <ci_upper_limit>164.73</ci_upper_limit>
            <estimate_desc>Point Estimate is the estimated ratio of exponentiated mean difference of log-transformed PK parameter from ANOVA. Confidence interval is obtained from ANOVA with hepatic function group as a fixed effect, and the subject as a random effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric LS Mean was used as PK parameters for unbound bexagliflozin by hepatic function group</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The acceptance range for bioequivalence is 80.00 - 125.00%.</non_inferiority_desc>
            <param_type>Point Estimate</param_type>
            <param_value>132.16</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.46</ci_lower_limit>
            <ci_upper_limit>181.08</ci_upper_limit>
            <estimate_desc>Point Estimate is the estimated ratio of exponentiated mean difference of log-transformed PK parameter from ANOVA. Confidence interval is obtained from ANOVA with hepatic function group as a fixed effect, and the subject as a random effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinary Glucose Excretion 0-48 Hours</title>
        <description>Pre-dose urine samples were collected from -12 to 0 h for baseline measurement of pharmacodynamic parameters. Post-dose urine samples were collected without preservative in four batches: 0 to 12 h, 12 to 24 h, 24 to 36h, and 36 to 48 h after dosing. Urine aliquots were prepared from well mixed collections for the assessment of pharmacodynamics.</description>
        <time_frame>0-48 hours</time_frame>
        <population>The Pharmacodynamic (PD) Population included all subjects without major protocol violations who were dispensed the study drug and produced at least the first 12 h post-dose urine. The PD Population was used to summarize the PD parameters. One subject in the Normal Hepatic Function group did not have the urinary glucose concentration measurement on the 36 to 48-hour urine collection.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Hepatic Function</title>
            <description>Healthy subjects with normal hepatic function. Each subject will receive a single oral dose of bexagliflozin, 20 mg.</description>
          </group>
          <group group_id="O2">
            <title>Moderate Hepatic Impairment</title>
            <description>Subjects with hepatic impairment conforming to the Child-Pugh class B (total score 7-9). Each subject will receive a single oral dose of bexagliflozin tablet, 20 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Glucose Excretion 0-48 Hours</title>
          <description>Pre-dose urine samples were collected from -12 to 0 h for baseline measurement of pharmacodynamic parameters. Post-dose urine samples were collected without preservative in four batches: 0 to 12 h, 12 to 24 h, 24 to 36h, and 36 to 48 h after dosing. Urine aliquots were prepared from well mixed collections for the assessment of pharmacodynamics.</description>
          <population>The Pharmacodynamic (PD) Population included all subjects without major protocol violations who were dispensed the study drug and produced at least the first 12 h post-dose urine. The PD Population was used to summarize the PD parameters. One subject in the Normal Hepatic Function group did not have the urinary glucose concentration measurement on the 36 to 48-hour urine collection.</population>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose (-12 - 0 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.045"/>
                    <measurement group_id="O2" value="0.91" spread="2.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 - 12 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.76" spread="7.253"/>
                    <measurement group_id="O2" value="29.57" spread="8.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 - 24 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.99" spread="5.780"/>
                    <measurement group_id="O2" value="19.25" spread="6.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 - 36 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.76" spread="14.588"/>
                    <measurement group_id="O2" value="20.96" spread="11.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 - 48 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.87" spread="4.785"/>
                    <measurement group_id="O2" value="5.11" spread="5.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 - 24 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.75" spread="12.497"/>
                    <measurement group_id="O2" value="48.82" spread="12.405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 - 48 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.92" spread="28.142"/>
                    <measurement group_id="O2" value="74.89" spread="25.410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse event data were collected from Day 0 up to Day 16 after drug administration</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Normal Hepatic Function</title>
          <description>Healthy subjects with normal hepatic function. Each subject will receive a single oral dose of bexagliflozin, 20 mg.</description>
        </group>
        <group group_id="E2">
          <title>Moderate Hepatic Impairment</title>
          <description>Subjects with hepatic impairment conforming to the Child-Pugh class B (total score 7-9). Each subject will receive a single oral dose of bexagliflozin tablet, 20 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Investigator does not have the right to publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Albert Collinson</name_or_title>
      <organization>Theracos Sub, LLC</organization>
      <phone>(508) 630-2129</phone>
      <email>acollinson@theracos.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

